JP2022552834A - ミエロペルオキシダーゼ阻害剤のプロドラッグ - Google Patents
ミエロペルオキシダーゼ阻害剤のプロドラッグ Download PDFInfo
- Publication number
- JP2022552834A JP2022552834A JP2022521147A JP2022521147A JP2022552834A JP 2022552834 A JP2022552834 A JP 2022552834A JP 2022521147 A JP2022521147 A JP 2022521147A JP 2022521147 A JP2022521147 A JP 2022521147A JP 2022552834 A JP2022552834 A JP 2022552834A
- Authority
- JP
- Japan
- Prior art keywords
- group
- substituted
- unsubstituted
- compound
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D515/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
- C07F9/65128—Six-membered rings having the nitrogen atoms in positions 1 and 3 condensed with carbocyclic rings or carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962913417P | 2019-10-10 | 2019-10-10 | |
| US62/913,417 | 2019-10-10 | ||
| PCT/US2020/054896 WO2021072140A1 (en) | 2019-10-10 | 2020-10-09 | Prodrugs of myeloperoxidase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022552834A true JP2022552834A (ja) | 2022-12-20 |
| JP2022552834A5 JP2022552834A5 (https=) | 2023-04-18 |
Family
ID=75438074
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022521147A Pending JP2022552834A (ja) | 2019-10-10 | 2020-10-09 | ミエロペルオキシダーゼ阻害剤のプロドラッグ |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240067651A1 (https=) |
| EP (1) | EP4041735A4 (https=) |
| JP (1) | JP2022552834A (https=) |
| KR (1) | KR20220080133A (https=) |
| CN (1) | CN114945573A (https=) |
| AU (1) | AU2020363903A1 (https=) |
| BR (1) | BR112022006381A2 (https=) |
| CA (1) | CA3157260A1 (https=) |
| IL (1) | IL291891A (https=) |
| MX (1) | MX2022004203A (https=) |
| WO (1) | WO2021072140A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021178734A1 (en) * | 2020-03-05 | 2021-09-10 | Biohaven Therapeutics Ltd. | Method of treating amyotrophic lateral sclerosis with myeloperoxidase inhibitor |
| CN115403584B (zh) * | 2021-05-26 | 2024-04-02 | 长春金赛药业有限责任公司 | 2-硫代-2,3-二氢嘧啶-4-酮衍生物、药物组合物及其制备方法和应用 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008522968A (ja) * | 2004-12-06 | 2008-07-03 | アストラゼネカ・アクチエボラーグ | 新規なピロロ［３，２−ｄ］ピリミジン−４−オン誘導体および治療でのその使用 |
| JP2010536849A (ja) * | 2007-08-23 | 2010-12-02 | アストラゼネカ・アクチエボラーグ | ハンチントン病及び多系統委縮症の処置のためのｍｉｐｏ阻害剤 |
| JP2013541494A (ja) * | 2010-06-24 | 2013-11-14 | アルカーメス ファーマ アイルランド リミテッド | Ｎｈ酸性化合物のプロドラッグ：エステル、カルボネート、カルバメートおよびホスホネートの誘導体 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU5436790A (en) * | 1989-04-19 | 1990-11-16 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Sulfer-containing xanthine derivatives as adenosin antagonists |
| WO2007069924A1 (en) * | 2005-12-15 | 2007-06-21 | Industrial Research Limited | Deazapurine analogs of 4'-aza-l-nucleosides |
| NZ544187A (en) * | 2005-12-15 | 2008-07-31 | Ind Res Ltd | Deazapurine analogs of 1'-aza-l-nucleosides |
| JP6667092B2 (ja) * | 2014-08-11 | 2020-03-18 | ハイドラ・バイオサイエンシーズ・リミテッド・ライアビリティ・カンパニーＨｙｄｒａ Ｂｉｏｓｃｉｅｎｃｅｓ， ＬＬＣ | ピロロ［３，２−ｄ］ピリミジン−２，４（３Ｈ，５Ｈ）−ジオン誘導体 |
| WO2016140879A1 (en) * | 2015-03-03 | 2016-09-09 | Biohaven Pharmaceutical Holding Company Ltd. | Riluzole prodrugs and their use |
| AU2018304508B2 (en) * | 2017-07-17 | 2021-06-10 | Astrazeneca Ab | MPO inhibitors for use in medicine |
-
2020
- 2020-10-09 CA CA3157260A patent/CA3157260A1/en active Pending
- 2020-10-09 KR KR1020227015015A patent/KR20220080133A/ko not_active Withdrawn
- 2020-10-09 AU AU2020363903A patent/AU2020363903A1/en not_active Abandoned
- 2020-10-09 CN CN202080070666.8A patent/CN114945573A/zh active Pending
- 2020-10-09 MX MX2022004203A patent/MX2022004203A/es unknown
- 2020-10-09 JP JP2022521147A patent/JP2022552834A/ja active Pending
- 2020-10-09 EP EP20874337.7A patent/EP4041735A4/en not_active Withdrawn
- 2020-10-09 US US17/766,539 patent/US20240067651A1/en not_active Abandoned
- 2020-10-09 WO PCT/US2020/054896 patent/WO2021072140A1/en not_active Ceased
- 2020-10-09 IL IL291891A patent/IL291891A/en unknown
- 2020-10-09 BR BR112022006381A patent/BR112022006381A2/pt not_active IP Right Cessation
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008522968A (ja) * | 2004-12-06 | 2008-07-03 | アストラゼネカ・アクチエボラーグ | 新規なピロロ［３，２−ｄ］ピリミジン−４−オン誘導体および治療でのその使用 |
| JP2010536849A (ja) * | 2007-08-23 | 2010-12-02 | アストラゼネカ・アクチエボラーグ | ハンチントン病及び多系統委縮症の処置のためのｍｉｐｏ阻害剤 |
| JP2013541494A (ja) * | 2010-06-24 | 2013-11-14 | アルカーメス ファーマ アイルランド リミテッド | Ｎｈ酸性化合物のプロドラッグ：エステル、カルボネート、カルバメートおよびホスホネートの誘導体 |
Non-Patent Citations (3)
| Title |
|---|
| B. D. ANDERSON, K. P. FLORA, 最新創薬化学 下巻, JPN6024013179, 25 September 1999 (1999-09-25), pages 280 - 281, ISSN: 0005447663 * |
| RAUTIO, JARKKO ET AL: "The expanding role of prodrugs in contemporary drug design and development", NATURE REVIEWS DRUG DISCOVERY, vol. 17(8), JPN6024013178, 2018, pages 559 - 587, ISSN: 0005447661 * |
| 原田直之: "抗腫瘍薬のプロドラッグ化−水溶性誘導体の設計と合成", 千葉大博士論文, JPN6024013176, 1998, pages 1 - 23, ISSN: 0005447662 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021072140A1 (en) | 2021-04-15 |
| IL291891A (en) | 2022-06-01 |
| KR20220080133A (ko) | 2022-06-14 |
| AU2020363903A1 (en) | 2022-03-24 |
| BR112022006381A2 (pt) | 2022-06-28 |
| MX2022004203A (es) | 2022-07-04 |
| US20240067651A1 (en) | 2024-02-29 |
| CN114945573A (zh) | 2022-08-26 |
| EP4041735A4 (en) | 2023-11-22 |
| CA3157260A1 (en) | 2021-04-15 |
| EP4041735A1 (en) | 2022-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2020200979B2 (en) | New substituted indazoles, methods for the production thereof, pharmaceutical preparations that contain said new substituted indazoles, and use of said new substituted indazoles to produce drugs | |
| US9643986B2 (en) | Factor D inhibitors useful for treating inflammatory disorders | |
| CN111787916B (zh) | 用于治疗疾病的二氢神经酰胺去饱和酶抑制剂 | |
| CN116332873A (zh) | 蛋白酪氨酸磷酸酶抑制剂及其使用方法 | |
| EP3590931A1 (en) | Amide derivative inhibitor and preparation method and application thereof | |
| US20110230461A1 (en) | 2,3-dihydro-1h-inden-1-yl-2,7-diazaspiro[3.5] nonane derivatives | |
| JP2012526097A (ja) | Ｇｐｒ１１９調節因子 | |
| JP2012526096A (ja) | Ｇｐｒ１１９調節因子 | |
| WO2012117219A1 (en) | Pyrrolidine derivatives as selective glycosidase inhibitors and uses thereof | |
| JP7295944B2 (ja) | Ｃｇｒｐアンタゴニストのプロドラッグ | |
| JP2022552834A (ja) | ミエロペルオキシダーゼ阻害剤のプロドラッグ | |
| EP3928779B1 (en) | Pharmaceutical containing sodium-dependent phosphate transporter inhibitor and phosphorus adsorbent for use in the prevention, treatment or suppression of chronic kidney disease, arteriosclerosis associated with vascular calcification, or ectopic calcification. | |
| JP6513075B2 (ja) | オートタキシン阻害活性を有する縮合ピラゾール誘導体 | |
| US9675584B2 (en) | Substituted indoles for the inhibition of PASK | |
| JP2013505290A (ja) | Ｇｐｒ１１９調節因子 | |
| EP4011865A1 (en) | Bridged heterocyclyl-substituted pyrimidine compound, preparation method therefor, and pharmaceutical use thereof | |
| EP4522158A2 (en) | Pak1 degraders and methods of use thereof | |
| WO2023235719A2 (en) | Stereoselective allosteric inhibitors of sarm1 | |
| US20260116923A1 (en) | Cyclic peptide il-1beta trap for the treatment of atherosclerosis and inflammatory disorders | |
| EP4268824A1 (en) | Imidazo[2,1-f][1,2,4]triazine derivatives useful as a medicament | |
| HK1242324B (zh) | 新型取代的吲唑、其制备方法、包含其的药物制剂及其用於制备药物的用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20220422 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20220426 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221209 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230410 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230410 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20240321 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240409 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20241029 |